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Treatment of C57BL/6 or NOD mice with a monoclonal antibody to
the CSF-1 receptor resulted in depletion of the resident macro-
phages of pancreatic islets of Langerhans that lasted for several
weeks. Depletion of macrophages in C57BL/6 mice did not affect
multiple parameters of islet function, including glucose response,
insulin content, and transcriptional profile. In NOD mice depleted
of islet-resident macrophages starting at 3 wk of age, several
changes occurred: (i) the early entrance of CD4 T cells and dendritic
cells into pancreatic islets was reduced, (ii) presentation of insulin
epitopes by dispersed islet cells to T cells was impaired, and
(iii) the development of autoimmune diabetes was significantly
reduced. Treatment of NOD mice starting at 10 wk of age, when
the autoimmune process has progressed, also significantly re-
duced the incidence of diabetes. Despite the absence of diabetes,
NOD mice treated with anti–CSF-1 receptor starting at 3 or 10 wk
of age still contained variably elevated leukocytic infiltrates in
their islets when examined at 20–40 wk of age. Diabetes occurred
in the anti–CSF-1 receptor protected mice after treatment with a
blocking antibody directed against PD-1. We conclude that treat-
ment of NOD mice with an antibody against CSF-1 receptor re-
duced diabetes incidence and led to the development of a
regulatory pathway that controlled autoimmune progression.
macrophage | islets of Langerhans | type 1 diabetes |
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Tissue-resident macrophages constitute a heterogeneous andmultifunctional cell type that populates virtually every tissue
(reviewed in refs. 1 and 2). In addition to their primary role as
sentinels for invading pathogens and as initiators of in-
flammation, macrophages have important homeostatic roles in
many tissue-specific processes such as development, metabolism,
and tissue remodeling, providing trophic factors within the tissue
microenvironment. Their homeostatic role is evidenced by the
deleterious phenotype that arises when macrophage develop-
ment is genetically constrained. The osteopetrotic mouse (op/op)
harbors a severe paucity of macrophages due to a null mutation
in the gene encoding the macrophage differentiation and survival
factor, colony stimulating factor-1 (CSF-1) (3). These mice
present with a number of developmental defects. Notably, the
islets of Langerhans, which normally contain a population of
CSF-1–dependent macrophages, are atrophic in the op/op
mouse, suggesting an integral role for macrophages during the
development of the endocrine pancreas (4, 5).
The pancreatic islets of all species contain a small number of
myeloid cells represented by macrophages. These macrophages
were first identified by immunohistochemical analysis using
macrophage-specific markers. Although initially thought to be
“passenger leukocytes,” subsequent studies using lineage tracing
approaches identified them as resident cells (5). These self-
replicate and are replaced minimally, if at all, by blood mono-
cytes. Islet macrophages are highly activated with a complex gene
transcriptome reflecting their interactions with beta cells and
with blood components (6). They express high levels of class II
histocompatibility molecules (MHC-II) and a number of cyto-
kines and chemokines including TNF-α and IL-1β (5, 6). The
islet macrophages are always next to blood vessels, in close
contact with beta cells, capture insulin-containing granules, and
present insulin peptides to autoreactive CD4 T cells (7). More-
over, macrophages extend filopodia into the vessel lumen and
can respond to blood stimuli (6, 8).
Our laboratory focuses on the early events that initiate auto-
immune diabetes as exemplified in the NOD mouse strain. Un-
derstanding the initiation of autoimmune diabetes is of
considerable clinical interest. Along those lines, identifying the
key cellular and molecular events that transition the immune-
privileged islet to an immunologically reactive environment is
paramount as it pertains to diabetes initiation. By 3 wk of age,
islets show significant cellular and molecular changes compared
with nondiabetic strains: an early entrance of CD4+ T cells re-
active to insulin in contact with the macrophages, a heightened
gene signature of activation in the macrophages, and the ap-
pearance of the XCR1+ subset of dendritic cells (DCs) (9, 10).
The deficit of XCR1+ DCs in the NOD Batf3−/− mice translates
into a profound reduction in the autoimmune process (10).
Here, we examine the role of the resident macrophages in
diabetogenesis. The islet macrophage expresses both inhibitory
and stimulatory ligands and receptors, as well as chemokines and
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chemokine receptors (6). They are the sole hematopoietic cell
within the islets before 3 wk of age and are able to present un-
conventional insulin epitopes to autoreactive T cells (6). Alto-
gether, this posits the intraislet macrophage as a key regulator of
lymphocyte entry into the islet. We have eliminated them using a
monoclonal antibody to the CSF-1 receptor (CSF-1R), AFS98
(11). This monoclonal antibody, and the M279 antibody against
CSF-1R, when administered in vivo resulted in the loss of mac-
rophages from many tissues (12–14). The extent of depletion
depended on the amount and frequency of administration (12).
Although treatment with AFS98 resulted in the loss of resident
macrophages, blood monocyte counts and inflammatory re-
sponses were not affected (13). We present evidence that the
anti–CSF-1R antibody AFS98 depleted the islet resident mac-
rophages in two strains of mice: the normal C57BL/6 (B6) and
the diabetogenic NOD. The depletion of macrophages did not
affect the metabolism or islet transcriptome of the mouse.
However, diabetes progression was severely blunted.
Results
Evaluation of C57BL/6 Mice. First, we evaluated the nondiabetic
B6 strain, following treatment with the monoclonal antibody
against CSF-1R. Injecting B6 mice with 0.25, 0.50, and 2.0 mg of
AFS98 led to a dose-dependent elimination of the intraislet
macrophages (Fig. 1A). This reduction was observed as early as
7 d after treatment and was equally evident at day 14. The de-
pletion was long lived. A 2.0-mg dose of AFS98 resulted in
elimination of the islet macrophage lasting for at least 6 wk (Fig.
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Fig. 1. Treatment of C57BL/6 mice with AFS98 antibody depleted their macrophages. (A) Female B6 mice aged 6–8 wk were administered 0.25, 0.50, or
2.0 mg of AFS98 antibody i.p. Islets were examined 7 and 14 d after injection for the presence of macrophages. Box indicates CD45+CD11c+MHCII+F4/
80+CD11b+ cells as a percent of total islet cellularity. (B) Female B6 mice aged 6–8 wk were treated with 2.0 mg of AFS98, and their islets were examined at the
time points indicated for the presence of macrophages. Top show the CD45+ cells, and Bottom show the CD45+CD11c+MHCII+ F4/80+CD11b+ cells as a percent
of total islet cellularity. (C) Graph of the CD45+ cells found in mice 1–2 wk after treatment with 2.0 mg of AFS98. (D) Graph of CD45+F4/80+CD64+ islet stromal
macrophage populations as a percent of CD45+ cells in control and AFS98-treated mice 2 wk after treatment. (E) Mice were treated for 1–2 wk with
AFS98 antibody, and the percent of total macrophages in lung, liver, spleen, and pancreatic lymph nodes were determined. (F) Macrophages were examined
as in E except plots show the percent of the indicated subpopulation of macrophages. For all graphs, controls were untreated age-matched mice. Flow
cytometry plots in A and B are representative of individual islet, lung, liver, spleen, and lymph nodes, from two to three experiments with two to four mice
per treatment group. Scatter plots in E and Fwere calculated from three independent experiments with two to three mice per group. P values were calculated
using Mann–Whitney U test with the following style: not significant (n.s., >0.1234), *P = 0.0332, **P = 0.0021, ***P = 0.0002, ****P < 0.0001.
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1B). Macrophages started to return to the islets by 6 wk and were
at normal levels by 7 wk after antibody treatment. The depletion
of macrophages in the islets was consistent over multiple ex-
periments (Fig. 1C). The macrophages of the stroma were also
affected by the AFS98 treatment. The macrophage reduction
was almost complete resulting in an ∼85% reduction compared
with control-treated mice (Fig. 1D and Fig. S1).
In addition to islets, several other tissues were examined. In
most, a set of the resident macrophages was also affected 7–14 d
after antibody administration. We analyzed total macrophages by
expression of F4/80 and CD64 and calculated their reduction as
shown in Fig. 1E. However, it was evident that the sensitivity to
AFS98 treatment was variable (Fig. 1F). In the lung, alveolar
macrophages were not affected, yet the CD11b+ interstitial
macrophages were depleted (15) (Fig. 1 E and F). In the liver,
there are two macrophage populations defined by expression of
F4/80. The F4/80hi Kupffer cells were reduced by about 50%
(Fig. 1 E and F). The F4/80int monocyte-derived macrophages
were almost completely depleted by AFS98 treatment. This last
finding suggest that these macrophages most likely represent the
recently identified liver capsular macrophages (16). The spleen
macrophages were not affected (Fig. 1 E and F). However, in the
pancreatic lymph node, a set of macrophages characterized by
CD11b (similar in surface marker expression to the lung interstitial
macrophages) were >80% reduced. Thus, not all tissue macro-
phages are as sensitive to anti–CSF-1R as the ones in the islets.
In summary, treatment with AFS98 led to variable effects on
the macrophages residing in various tissues, while in islets, the
effects were pronounced and prolonged. We also evaluated
whether AFS98 treatment could affect the number of T and B
cells and their differentiation in thymus and bone marrow. We
found no impairment in their numbers and differentiation pat-
terns in thymus or bone marrow (Fig. S2).
As seen in the op/op mouse, the absence of macrophages from
birth can lead to systemic disruption of mouse homeostasis.
Therefore, we evaluated two basic parameters of islet function
after macrophage depletion: glucose tolerance and beta-cell in-
sulin content. The glucose tolerance test measures the ability of
the beta cell to sensor and respond to glucose, release insulin,
and return the mouse to euglycemia. Following treatment of the
B6 mice with the AFS98 antibody, neither glucose tolerance nor
insulin content was affected (Fig. 2 A and B). Glucose tolerance
was unimpaired even after 6 wk of macrophage depletion in the
islets (Fig. 2A). Measured pancreatic insulin content was stable
at 3 wk after depletion (Fig. 2B).
A more global and unbiased measure of islet health is to
evaluate the whole transcriptome. B6 mice were treated with
2.0 mg of AFS98 or control IgG2a at 3 wk of age, and whole islets
were isolated at 6 wk of age. Comparison of AFS98 versus IgG2a-
treated mice revealed 16 differentially expressed transcripts at a
twofold change and 99% confidence interval in whole islets (Fig.
2C). These 16 changes were in transcripts known to be encoded
strictly by the macrophage. These included transcripts previously
reported to be up-regulated during diabetes progression (9).
Therefore, the majority of the islet transcriptome was not sig-
nificantly affected by macrophage depletion, and the only change
was the loss of the islet macrophage. In conclusion, homeostasis
of islet function was not affected in a detectable manner when
macrophages were depleted several weeks after birth.
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Fig. 2. Islet function after depletion of macrophages by AFS98. (A) B6 mice were given 2.0 mg of AFS98 i.p. at 6–8 wk of age. Glucose tolerance assays were
then performed on AFS98-treated and untreated mice. After the indicated number of days, the mice were fasted for 12 h and then injected with 2.0 g/kg
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group). (B) Nine-week-old B6 females were left untreated or administered 2.0 mg of AFS98 i.p. Four days later, the mice were placed on a 20% sucrose diet for
an additional 7 d, then returned to a normal diet for 2 d. The mice were then killed, and the insulin content of their islets was measured (n = 5 mice per
group). (C) Three-week-old C57BL/6 mice were left untreated or administered 2.0 mg of AFS98 i.p. At 6 wk of age, their islets were isolated, total RNA was
extracted, and transcripts were analyzed by microarray. Scatter plot shows the log2 mean expression values for four control and experimental mice. The dots
highlighted in blue represent genes differentially expressed between treated and control mice at 99% confidence using moderated t test with Benjamini–
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Evaluation of NOD Mice.
Islets. Similar to the results observed in B6 mice, Fig. 3A shows
that treatment with 0.5 or 2.0 mg of AFS98 depleted the islet
macrophages in 4- to 5-wk-old NOD mice. Comparable results
were obtained following treatment of NOD.Rag1−/− mice with
the AFS98 antibody (Fig. S3). An analysis of NOD mice at
3–4 wk of age showed that the initial islet infiltrating T cells were
all CD4+ and mostly in contact with the intraislet macrophage
(9). The islet macrophages express CD11b, CD11c, and MHC-II
highly on their surface. At this 3–4 wk of age period, there are
very few XCR1+ DCs in islets (10).
We confirmed the colocalization of CD4 T cells with intraislet
macrophages by examining islets using two-photon microscopy.
NOD mouse islets were examined at 3–4 wk of age, the earliest
age where one can identify the initial infiltrating T cells. Indeed,
27% of NOD islets had CD4 T cells, 70% of which were in
contact with the F4/80+ macrophages, confirming our initial
studies. In the mice that were injected with 0.5 mg of anti–CSF-
1R at 2 wk of age, the islets did not harbor any myeloid cells at
4 wk of age. In these mice, only 3% of islets had a detectable
CD4 T cell.
Next, we examined insulin peptide presentation by isolating
the islets, dispersing the cells, and culturing them with insulin-
reactive CD4 T cell hybridomas. Depletion of islet macrophages
resulted in marked reduction of presentation to two different
CD4 T cell hybridomas recognizing different MHC-II epitopes
of insulin (17). The addition of the cognate peptides reflects the
availability of MHC-II+ presenting cells. As noted in Fig. 3B, this
addition did not lead to presentation in the islets of the treated
mice, reflecting the paucity of presenting cells and the inability of
any other islet cell to express MHC-II or present peptide. The
same findings were reproduced in B6.g7 mice (Fig. S4).
Lymph node responses. While the islets from the macrophage-
depleted mice were impaired in antigen presentation, this was
not the case in the peripheral lymph nodes. This was determined
using two approaches: carboxyfluorescein succinimidyl ester
(CFSE) dilution of transferred T cells and recall response by
ELISpot. For CFSE dilution experiments, we transferred CD4
(BDC2.5) or CD8 (NY8.3) T cell clones into control or AFS98-
treated NOD. BDC2.5 responds to a chromogranin peptide in
the context of I-Ag7 (18), while the NY8.3 T cell divides in re-
sponse to a peptide derived from IGRP, the islet-specific glu-
cose-6-phosphatase–dependent catalytic subunit-related protein,
in the context of H-2Kd (19, 20). Fig. 4 A and B shows that both
T cell clones proliferated in the draining pancreatic lymph node,
but not in the distant inguinal lymph node. Next, to determine if
depletion of the islet macrophage affected the trafficking of di-
abetogenic cells to the islets, we examine the entrance of TCR
transgenic T cells into them. Both BDC2.5 and NY8.3 T cells
entered islets of control mice but neither entered the islets from
AFS98-treated mice (Fig. 4C). While the T cells entered and
reacted to antigen presented in the pancreatic lymph node, this
was not the case in the islets.
In the second approach, AFS-treated mice were immunized
with various autoreactive peptides in the footpads and the T cell
response was tested a week later; there was no impairment of the
response (Fig. 5). Immunization with the insulin B:9–23 peptide
elicited an IL-2 and IFN-γ response to the peptide but not to the
insulin protein, as reported before (17). Immunization with
peptides from IGRP known to elicit CD4 or CD8 T cell re-
sponses was also unaffected by AFS98 treatment. The CD4 or
CD8 T cell responses to the foreign protein hen egg lysozyme
(HEL) were also unaffected.
In brief, examination by flow cytometry, direct microscopy of
islets, antigen presentation assays, and T cell migration assays
shows that the lack of macrophages translates into an absence of
early CD4 T cell infiltration and antigen presentation capability
of the islets. In contrast, the lymph nodes in the AFS-treated
mice were active in antigen presentation.
Diabetes. Female NOD mice were followed for diabetes after
treatment with AFS98 or control rat IgG2a antibody. In two
experiments, mice were treated at 2–3 wk of age, a time when the
diabetogenic process is starting in limited islets. The treatment
was continued for several weeks using two different concentra-
tions of antibody. In a third experiment, NOD mice were treated
starting at 10 wk of age, a time when the diabetogenic process is
active and most islets are already infiltrated by both CD4 and
CD8 T cells. Both treatments led to a marked reduction in di-
abetes incidence when the mice were followed for 40 wk. The
pooled results are shown in Fig. 6A. Fig. 6C shows the results of
the individual experiments. Combining the three experiments,
4 of 40 AFS98-treated mice and 24 of 39 of the control mice
became diabetic.
At the end of the 40–42 wk of observation, two manipulations
were performed on the AFS98-treated mice. First, the mice were
administered an anti–PD-1 monoclonal antibody and this led to
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Fig. 4. AFS98 treatment does not affect T cell division in lymph nodes but prevents T cell entry into islets of Langerhans. NOD mice were injected with
AFS98 antibody at a dose of 0.5 mg at 2 wk of age and 2.0 mg at 4 wk of age. Two TCR transgenic T cells, the CD4+ BDC2.5 and the CD8+ NY8.3, were isolated
from lymph nodes and spleens of their respective mice. T cells were then labeled with CFSE and transferred into 6-wk-old NOD mice that had either been left
untreated or treated with AFS98. (A and B) Seven days after T cell transfer, the pancreatic and inguinal lymph nodes were isolated and analyzed by flow
cytometry. (A) Dilution of CFSE in either inguinal (Upper) or pancreatic (Lower) lymph nodes for an individual mouse per treatment is shown. Cells were gated
on forward and side-scatter, CD45, CD3, and either CD4 (BDC2.5) or CD8 (NY.8.3). (B) Summary of division index and proliferation index for individual mice
examined as in A. Results show three or four individual mice per group. (C) Ten days after TCR transgenic T cell transfer, islets of Langerhans were isolated and
examined for entry of either the BDC2.5 or NY8.3 T cells by flow cytometry. The Left two images are gated on forward and side-scatter, CD45, and CD3. The
Right images are gated on forward and side-scatter. BDC T cells were identified using a clonotypic antibody to its T cell receptor. NY8.3 T cells were identified
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the rapid development of diabetes in 7 of 7 of the mice evaluated
(Fig. 6C). Others have found a profound regulatory effect of the
PD-1/PD-L1 pathways in regular diabetogenesis, and at least this
pathway is operational following AFS98 treatment (21–23).
Anatomically, insulin-reactive T cells express PD-1, while in is-
lets the beta cells, vascular endothelium, macrophages, and in-
flammatory DCs express high levels of PD-L1 (21, 24, 25).
Second, splenocytes from the AFS98-treated mice were
transferred into NOD.Rag1−/− mice. NOD splenocytes transfer
disease to normally nondiabetic NOD.Rag1−/− mice and is used as
a measure of the diabetogenic potential of the T cells in the NOD
mouse following genetic or pharmaceutical manipulations. The
mice first treated with AFS98 at the 2- to 3-wk period transferred
diabetes poorly; only 1 of 14 became diabetic 20 wk after transfer
(Fig. 6 B and C). In contrast, splenocytes from 10-wk, AFS98-
treated NOD mice transferred diabetes to 8 of 8 recipients.
We also examined the islets for their leukocyte content at
various time points after their treatment with AFS98. Fig. 7 shows
results from mice treated at 2–3 wk of age. AFS98 treatment
resulted in a reduction of total leukocytes (CD45+) from ∼10% in
controls to ∼1% in the treated mice by 8 wk after treatment (Fig.
7A). There was also a reduction of F4/80+ macrophages from
∼4% of total islet cellularity to undetectable levels. Over time, the
control NODmice showed progressive increase in the CD45+ cells
(Fig. 7B). After the end of the observation period—at 44 wk—a
number of the islets from AFS-treated mice were infiltrated. We
observed two phenotypes: 4 of 8 mice contained ∼20–25% CD45+
cells in the islets, and 4 of 8 mice contained 2–5% CD45+ cells in
the islets (Fig. 7 C and D). (The IgG-treated control NOD mice
contained ∼60–70% CD45+ cells in islets.) Corroborating the flow
cytometry ∼50% of the pancreata examined had a degree of peri-
insulitis (Fig. 7E). However, the other 50% of pancreata examined
showed little to no insulitis (Fig. 7F). Therefore, macrophage
depletion is protective in NOD mice long term, despite the in-
filtration or expansion of leukocytes in ∼50% of the mice.
In mice treated with AFS98 starting at 10 wk of age, there also
was a reduction in the number of leukocytes in islets at 22 wk of
age. However, by 40 wk of age, all of the mice had comparable
infiltrates to a 22-wk-old NOD mouse (Fig. 8). Thus, late mac-
rophage depletion does not stop the infiltration of islets, despite
preventing the development of hyperglycemia.
These results suggest that macrophage depletion can act be-
fore and after the diabetogenic T cell pool in the NOD has fully
developed. Early AFS98 treatment blocks diabetes by eliminat-
ing a key antigen-presenting cell in islets, preventing early entry
of activated T cells, and limiting the expansion of the di-
abetogenic T cells. In contrast, in late-treated NOD mice, there
are active diabetogenic T cells but disease is controlled by the
development of a regulatory condition through at least one
mechanism, PD-1/PD-L1 interaction. In both situations, we find
islet infiltration with preservation of islet function.
Discussion
Injection of NOD mice with antibodies directed against CSF-1R
depleted the islet resident macrophages while having a variable
effect on macrophages of secondary lymphoid tissues and various
other organs. The treatment had a profound effect in the de-
velopment of diabetes. The manner in which the islet macro-
phage was eliminated by the antibody treatment is not clear,
although it does not involve an acute inflammatory reaction (14).
The islet transcriptome analysis displayed no up-regulation of
inflammatory transcripts following macrophage depletion (Fig.
2C). CSF-1R signaling is crucial for sustaining macrophage via-
bility, which is most likely the reason for its loss following the
antibody treatment (11).
There are two distinct scenarios that likely contributed to the
attenuation of the active autoimmune process: (i) the impair-
ment of islet antigen presenting function and (ii) the develop-
ment of a regulatory process. Concerning the islets, these studies
confirm the centrality of the resident macrophage in the patho-
physiology of pancreatic islets. The islet macrophage arises
during embryonal development. It is required for the early de-
velopment of islets and during postnatal growth as is evident in
the op/op mouse that lack CSF-1 (4, 5). However, in adult mice,
islet function is not impaired when the macrophage is absent
(our studies in B6 mice). We have not probed other possible
roles for the islet macrophage such as maintaining vessel per-
meability, protecting against infectious agents, or modulating the
physiology of beta cells. The islet macrophage is highly activated,
as evidenced by their expression of TNF and IL-1 transcript and
protein, and high expression levels of MHC-II (5, 10). In the
context of autoimmunity, such as in NOD mice, autoreactive
T cells escape thymic control and enter islets whereupon they
establish long-lived contact with the macrophage (26).
The macrophage-depleted islet per se was impaired in its ca-
pacity to receive diabetogenic T cells. In their absence, lym-
phocyte entry into islets was impaired. The immunofluorescence
and two-photon imaging of isolated islets showed the majority of
CD4 T cells in islets in contact with the macrophage. Indeed,
previous analyses showed macrophage filipodia extending into
the blood vessel lumens (8). I.v. injecting 0.5-μm latex beads
coated with antibodies to I-Ag7 localized the beads to the mac-
rophage/blood vessel interface. These findings point to the
macrophage filopodia as the anatomical element that captures
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NOD mice were treated with 2 mg of AFS98 antibody for 1 wk and then
injected with 10 nmols INS:9–23, HEL, or IGRP peptides in complete Freund’s
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cate or triplicate.
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the diabetogenic CD4 T cells, while the high-expression MHC-II
may well be the key molecular substrate (8). In sum, the present
and past studies point to the macrophages as the beacon, the true
gatekeeper for entrance of lymphocytes into the islet.
Three pointed findings followed the initial depletion of mac-
rophages. First, the effect of AFS98 treatment applied to mice
already undergoing an active diabetogenic process. At 10 wk of
age, the autoimmune process is progressing; our own studies
showed a striking inflammatory signal at this time. However,
AFS98 treatment at this time was effective. This indicates that
AFS98 inhibits when there are active diabetogenic T cells. Thus,
the inhibitory effect of macrophage depletion is not necessarily
accounted for by a lack of T cell priming. Second is that after the
period of macrophage depletion, the islet becomes progressively
receptive to the entrance of T cells and new macrophages. This
was evident when examining the islets by flow cytometry. Despite
this renewed accumulation of leukocytes into the islets, the beta
cells were preserved. Histological examination at the 42-wk pe-
riod showed the preservation of beta cells, albeit many islets
showed the peri-insulitic lesion next to otherwise normal beta
cells. This finding suggests that the newly arriving monocyte-
derived macrophages or other cells in islets or in lymph nodes
are not driving forward the process and may participate by
controlling it. For example, the incoming macrophages may
be inhibitory in a way akin of what happens in the tumor envi-
ronment. Finally, a regulatory process involving the PD-1 and
PD-L1 interacting molecules was evident. The mice protected
by AFS98 until over 40 wk of age developed diabetes if given
anti–PD-1. At face value, this result tells us that the active pro-
cess had been under checkpoint control following the initial
macrophage deletion.
Future studies should examine the site of the control pathway,
whether it is the lymph nodes or the islets, many of which had the
peri-insulitic lesion. In NOD diabetogenicity, peripheral lymph
nodes play a key role in the early program of the autoimmunity
(27–29). We did show here that the lymph nodes after AFS
treatment could be an effective site of presentation of either
diabetogenic or foreign antigens. It is not because of the lack of
presenting function in lymph nodes that diabetes is curtailed.
However, the nodes could be the anatomical substrate of the
regulatory process involving the PD-1/PD-L1 pathway. The
lymph nodes are depleted of their resident macrophages, albeit
not to the extent as islets. Thus, the presentation that results in
the activation of the PD-1/PD-L1 activation could be caused by
DC or B cells. Lymph node macrophages at face value would
foster positive interactions in a normal situation but, in their
absence, would drive the process into a regulatory pathway. In
our early studies, we did find that the F4/80 positive macro-
phages were capable of presenting minor epitopes of insulin.
Various inflammatory processes have been studied with vari-
able results using antibodies to transiently remove tissue mac-
rophages (30–35). Other treatment modalities have targeted
blood monocytes. Clodronate-liposome treatment depletes cir-
culating monocytes and affected a number of inflammatory re-
actions (36). These treatments over repeated periods of time
resulted in the reduction in diabetes in NOD mice (36–40). In
all of these instances, the reduction resulted in the loss of
inflammatory macrophages, i.e., macrophages derived from
monocytes that participated as effectors in the diabetogenic
process. A study by Calderon et al. (41) showed that resident
macrophages were not affected by injections of clodronate li-
posomes, although diabetes induced by the transfer of the acti-
vated BDC2.5 CD4+ T cells was affected. Diabetes induced by
such transfer required the presence of new macrophages as ef-
fector cells modulated by IFN-γ production from activated
T cells (42).
Integrating our findings with these, it is evident that macro-
phages have two distinct functions in autoimmune diabetes:
First, as evident here, as a cell controlling the development and
progression of the diabetogenic process, and second, as an ef-
fector cell once islet inflammation is induced.
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Materials and Methods
Mice. Female C57BL/6 mice (B6), female NOD/ShiLtJ (NOD), NOD.129S7(B6)-
Rag1tm1Mom/J (NOD.Rag1−/−), NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/DoiJ
(BDC2.5), and NOD.Cg-Tg(TcraTcrbNY8.3)1Pesa/DvsJ (NY8.3) mice were
purchased from the Jackson Laboratories and bred in house. NY8.3 mice
were backcrossed onto the congenic NOD.B6-Ptprcb/6908MrkTacJ (NOD.
CD45.2) background for T cell transfer experiments (18). All mouse experi-
ments were performed in accordance with the Division of Comparative
Medicine of Washington University School of Medicine [Association for As-
sessment and Accreditation of Laboratory Animal Care (AAALAC) accredi-
tation no. A3381-01].
T Cell Transfer Assay; ELISPOT; Anti–PD-1 Treatment. 8F10, BDC2.5, and NY8.3
TCR transgenicmouse spleens and lymph nodeswere harvested and dispersed
into single-cell suspensions. CD4- or CD8-positive cells were selected via
magnetic microbead cell separation (Miltenyi Biotech) according to the
manufacturer’s protocol. The cells were then stained with 1 μM carboxy-
fluorescein diacetate succinimidyl ester (Life Technologies) for 15 min at
37 °C and immediately quenched with 4 °C DMEM supplemented with 10%
FCS. CFSE-labeled cells (3.0 × 106) were then transferred into recipient mice
via tail vein injections. Islets, draining pancreatic lymph nodes, and inguinal
lymph nodes were harvested, dispersed into single-cell populations, and
stained with fluorescent antibodies for analyses by flow cytometry. For ex-
periments dealing with anti–PD-1, AFS98-treated or control NOD mice were
injected with 200 μg of antibody three times over 6 d (days 0, 3, and 6; Anti–
PD-1 clone RMP1-4; Leinco Technologies). Mice were then followed for di-
abetes incidence. For experiments examining the lymph node response by
ELSIPOT, B6.g7 or NOD mice (7–10 wk old) were treated with a single 2.0-mg
dose of AFS98 or control rat IgG2a. Seven days later, the mice were immu-
nized in the footpad with 10 nmol INS B:9–23 peptide, HEL protein (Sigma-
Aldrich), or IGRP:206–214 peptide. After 7 d, the animals were killed and the
popliteal lymph nodes were removed and made into single-cell suspensions.
Lymph nodes were assayed for reactivity by eliciting a recall response on
either IL-2 or IFN-γ–coated 96-well multiscreen plates (MilliporeSigma) for
ELISPOT. One million popliteal lymph node cells were plated per well with
10 μM antigen, and reactive cells were counted using Immunospot Software
(C.T.L.). Immune responses in mice challenged with INS B:9–23 peptide were
recalled with either insulin or INS B:9–23. Immune responses in mice chal-
lenged with HEL protein were recalled with either HEL protein or HEL
peptides 11–25 (CD4 epitope) or 20–35 (CD8 epitope). Finally, responses in
mice challenged with IGRP:206–214 peptide were recalled with either
IGRP:128–142 (CD4 epitope) or IGRP:206–214 (CD8 epitope).
Glucose Tolerance Assay and Insulin Quantitation. For glucose tolerance ex-
periments, female B6mice weremaintained on a normal diet and then fasted
overnight for 12 h. Fasting blood glucose levels were tested before a chal-
lenge with 1.5 g/kg glucose in PBS (Life Technologies) administered by i.p.
injection. Blood glucose was measured at the intervals indicated in the ex-
periments. For insulin quantitation, control or αCSF-1R–treated mice were
maintained on 20% sucrose water for 7 d, returned to regular water for an
additional 2 d, fasted overnight, and then their pancreata were removed
and weighed. Pancreata was minced and homogenized. The supernatant
was collected after pelleting the homogenate, and insulin was quantified
using the Rat Insulin Radioimmune Assay (MilliporeSigma), as per the
manufacturer’s instruction.
Antigen Presentation Assay. Islets were dispersed nonenzymatically, and 4.0 ×
104 islet cells per well were plated together in a 96-well plate with 5.0 × 104
T cell hybridoma cells per well, in DMEM containing 10% FCS and 5 mM or
25 mM glucose (low or high glucose media, respectively). After 24 h, the
supernatants were removed and the production of IL-2 was measured by
culturing supernatants in the presence of the IL-2–dependent cell line, CTLL-2.
Proliferation of CTLL-2 cells was measured by the incorporation of 3[H] thy-
midine. For the antigen presentation assays, the 8F10 and IIT3 T cell hybrid-
omas directed to the insulin B:12–20, and B:13–21 epitopes, respectively, were
used (7).
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Histology and Imaging. Microscopy imaging was performed using an Eclipse
E800 microscope (Nikon) equipped with CFI Plan Apo Lambda DM 20× air
objective, X-Cite 120PC light source (Excelitas Technologies), EXi blue fluo-
rescence microscopy camera, and QCapture 64-bit v2.9.13 acquisition soft-
ware (QImaging).
Islets, Pancreatic Stroma, and Lymph Node Isolation. Pancreata were perfused
through the common bile duct with 5.0 mL of calcium-free HBSS supple-
mented with 400.0 μg/mL of collagenase. Pancreata were then removed, and
digested in a 37 °C water bath followed by vigorous shaking for 90 s, washed
three times in HBSS, and then passed through a 70.0-μm strainer to retain
the islets. Cells that passed the through the strainer represented the pan-
creatic stroma and were filtered a second time through a 40.0-μm filter to
prepare a single-cell suspension. Islets retained on the 70.0-μm filter were
then flushed into a Petri dish for hand-picking using a zinc-chelating dye,
Dithizone (200 μg/mL 10% DMSO PBS; Sigma), to identify the islets. Hand-
picked islets were then dispersed using Cell Dissociation Solution Non-
Enzymatic (Sigma) for 10 min at 37 °C. Lymph nodes and spleens were
digested by incubation at 37 °C in DMEM supplemented with 10% fetal calf-
serum, 125 μg/mL Liberase TL (Roche Life Science), and 50 μg/mL DNase I
(Roche Life Science). All single-cell suspensions were then incubated with
2.4G2 conditioned media (PBS, 1% BSA, and 50% 2.4G2 in DMEM) at 4 °C for
15 min to block FC receptors. Samples were then stained with fluorescent
antibodies for flow cytometry or sorting.
Antibodies for Flow Cytometry and Sorting. Flow cytometry data were ac-
quired on a FACSCanto II (BD Biosciences) and analyzed on FlowJo
v10.2 software (FlowJo, LLC). Cell sorting was performed using a FACSAria II
(BD Biosciences). The following antibodies were purchased from BioLegend:
BV510 anti-CD45 (30-F11), Pacific Blue (PB) anti–I-A/I-E (pan MHC-II), FITC
anti-CD3 (2C11), FITC and APC anti-F4/80 (BM8), PE-Cy7 anti-CD11b (M1/70),
PE anti-CD103 (2E7), PerCP-Cy5.5 anti-Ly6C (AL-21), PerCP-Cy5.5 anti-B220
(RA3-6B2), and APC anti-CD64 (X54-5/7/1). APC-eFluor780 anti-CD11c
(N418), PerCP-eFluor710 anti-CD8 (53-6.7), eFluor450 anti–Ki-67 (SolA15),
and APC FoxP3 (FJK-16) were purchased from eBioscience. For intracellular
staining, the FoxP3 Fix/Perm kit (eBioscience) was used according to the
manufacturer’s instructions.
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Fig. S1. Pancreatic stromal macrophages are reduced following AFS98 treatment. B6 mice were treated as in Fig. 1 and analyzed for the presence of CD45+F4/
80+CD64+ macrophages. Numbers indicate the percentage of macrophages in the pancreatic stroma as a percent of the CD45+ cells. Cells were gated on FSC/
SSC/CD45+. Data are taken from two independent mice per group and is representative of two independent experiments.
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Fig. S3. AFS98 depletes islet macrophages in the NOD.Rag1−/−mouse. Female NOD.Rag1−/− mice were treated at 4 wk of age with 2 mg of either rat IgG2a or
ASF98 and then sampled at 6 wk of age. (A and B) Islet leukocytes cells were analyzed by flow cytometry. Cells were gated by forward and side scatter and then
plotted for CD45 (Left). Next, cells were gated on CD45+CD11c+I-Ag7+, and the F4/80 by CD103 cells were plotted (Right). Values represent the percent of each
box as a function of total islet cellularity. (B) Scatter plots of the percent of CD45+ or F4/80+CD45+CD11c+I-Ag7+ in two individual mice per group.
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Fig. S4. Depletion of macrophages blocks MHC-II antigen presentation by whole islet cells. Antigen presentation was performed as in Fig. 3B except with
6-wk-old B6.g7 mice that were given 2 mg of either control or AFS98 antibody at 4 wk of age. Left shows the CTLL-2 assay for an anti-insulin CD4 T cell
hybridoma. Right shows the peptide curve of the hybridoma using an immortalized cell line as APC.
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